Email Alert | RSS

北京大学学报（医学版） ›› 2023, Vol. 55 ›› Issue (6): 966-974. doi: 10.19723/j.issn.1671-167X.2023.06.003

• 论著 • 上一篇    下一篇

系统性红斑狼疮及成人Still病合并巨噬细胞活化综合征的临床特点及诊断指标

姚海红1,杨帆1,2,唐素玫1,张霞1,何菁1,贾园1,*()   

  1. 1. 北京大学人民医院风湿免疫科, 北京 100044
    2. 首都医科大学附属北京友谊医院风湿内科, 北京 100050
  • 收稿日期:2023-09-01 出版日期:2023-12-18 发布日期:2023-12-11
  • 通讯作者: 贾园 E-mail:jiayuan1023@sina.com
  • 基金资助:
    国家自然科学基金(81801618)

Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease

Hai-hong YAO1,Fan YANG1,2,Su-mei TANG1,Xia ZHANG1,Jing HE1,Yuan JIA1,*()   

  1. 1. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China
    2. Department of Rheumatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
  • Received:2023-09-01 Online:2023-12-18 Published:2023-12-11
  • Contact: Yuan JIA E-mail:jiayuan1023@sina.com
  • Supported by:
    the National Natural Science Foundation of China(81801618)

RICH HTML

   

PDF (PC)

摘要：

目的: 分析和比较系统性红斑狼疮(systemic lupus erythematosus，SLE)和成人Still病(adult-onset Still’s disease，AOSD)合并巨噬细胞活化综合征(macrophage activation syndrome，MAS)患者的临床及实验室指标特点，评估已有的2016年欧洲抗风湿病联盟/美国风湿病学会/儿童风湿病国际试验组织发布的全身型幼年特发性关节炎(systemic juvenile idiopathic arthritis，sJIA)合并MAS(sJIA-MAS)分类标准在不同自身免疫病背景下的适用情况, 并提出新的诊断预测指标，为提高MAS早期诊断率、改善患者预后提供参考。方法: 回顾性分析2000—2018年在北京大学人民医院住院的24例SLE合并MAS患者和24例AOSD合并MAS患者的临床及实验室数据，分别与同期未发生MAS的50例SLE及50例AOSD患者进行比较，通过受试者工作特征(receiver operating characteristic，ROC)曲线确定预测MAS的实验室指标截断值。进一步使用实验室诊断预测值对2016年sJIA-MAS分类标准进行改进，探讨改进后的标准对于AOSD合并MAS的适用性。结果: 约60%的SLE合并MAS及40%的AOSD合并MAS患者发生在原发病确诊后的3个月内。发热是MAS最常见的临床表现。实验室指标除了2004年国际组织细胞学会修订的噬血细胞综合征诊断标准中的指标外，MAS患者的天冬氨酸转氨酶及乳酸脱氢酶也显著升高，白蛋白显著下降，噬血现象仅见于约50%的MAS患者。ROC曲线分析显示，当SLE患者铁蛋白≥1 010 μg/L、乳酸脱氢酶≥359 U/L，AOSD患者纤维蛋白原≤225.5 mg/dL、甘油三酯≥2.0 mmol/L时，对MAS诊断有最好的区分价值。将2016年sJIA-MAS分类标准应用于AOSD合并MAS，诊断的敏感性和特异性分别为100%和62%，对其中特异性低的铁蛋白和纤维蛋白原条目进行改进，诊断特异性可升高为86%。结论: SLE合并MAS及AOSD合并MAS最常发生于疾病确诊后的早期，不同疾病继发MAS因受自身免疫病特点的影响而在实验室指标方面存在明显差异，以同一标准进行MAS诊断可能导致误诊或漏诊。2016年sJIA-MAS分类标准在AOSD合并MAS诊断中敏感性高而特异性低，对之进行改进可提高特异性。

关键词: 巨噬细胞活化综合征, 噬血细胞性淋巴组织细胞增多症, 系统性红斑狼疮, 成人Still病, 诊断

Abstract:

Objective: To analyze and compare the clinical and laboratory characteristics of macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE) and adult-onset Still's disease (AOSD), and to evaluate the applicability of the 2016 European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organization classification criteria for MAS complicating systemic juvenile idiopathic arthritis (sJIA) in different auto-immune diseases contexts and to propose new diagnostic predictive indicators. Methods: A retrospective analysis was conducted on the clinical and laboratory data of 24 SLE patients with MAS (SLE-MAS) and 24 AOSD patients with MAS (AOSD-MAS) who were hospitalized at Peking University People's Hospital between 2000 and 2018. Age- and sex-matched SLE (50 patients) and AOSD (50 patients) diagnosed in the same period without MAS episodes were selected as controls. The cutoff values for laboratory indicators predicting SLE-MAS and AOSD-MAS were determined using receiver operating characteristic (ROC) curves. Furthermore, the laboratory diagnostic predictive values for AOSD-MAS were used to improve the classification criteria for systemic juvenile idiopathic arthritis-associated MAS (sJIA-MAS), and the applicability of the revised criteria for AOSD-MAS was explored. Results: Approximately 60% of SLE-MAS and 40% of AOSD-MAS occurred within three months after the diagnosis of the underlying diseases. The most frequent clinical feature was fever. In addition to the indicators mentioned in the diagnosis criteria for hemophagocytic syndrome revised by the International Society for Stem Cell Research, the MAS patients also exhibited significantly elevated levels of aspartate aminotransferase and lactate dehydrogenase, along with a significant decrease in albumin. Hemophagocytosis was observed in only about half of the MAS patients. ROC curve analysis demonstrated that the optimal discriminative values for diagnosing MAS was achieved when SLE patients had ferritin level≥1 010 μg/L and lactate dehydroge-nase levels≥359 U/L, while AOSD patients had fibrinogen levels≤225.5 mg/dL and triglyceride levels≥2.0 mmol/L. Applying the 2016 sJIA-MAS classification criteria to AOSD-MAS yielded a diagnostic sensitivity of 100% and specificity of 62%. By replacing the less specific markers ferritin and fibrinogen in the 2016 sJIA-MAS classification criteria with new cutoff values, the revised criteria for classifying AOSD-MAS had a notable increased specificity of 86%. Conclusion: Secondary MAS commonly occurs in the early stages following the diagnosis of SLE and AOSD. There are notable variations in laboratory indicators among different underlying diseases, which may lead to misdiagnosis or missed diagnosis when using uniform classification criteria for MAS. The 2016 sJIA-MAS classification criteria exhibit high sensitivity but low specificity in diagnosing AOSD-MAS. Modification of the criteria can enhance its specificity.

Key words: Macrophage activation syndrome, Hemophagocytic lymphohistiocytosis, Systemic lupus erythematosus, Adult-onset Still's disease, Diagnosis

中图分类号: 

  • R593.2

表1

HLH患者人口学特征及主要临床和实验室特征"

Items AOSD-MAS (n=24) SLE-MAS (n=24) LYM-HLH (n=20)
Epidemiological features
  Female 21/24 (87.5) 20/24 (83.3) 9/20 (45.0)*#
  Age at diagnosis of HLH/years 34.7±15.2 40.0±15.2 49.1±20.0*
  Age at diagnosis of AD or LYM/years 33.0±16.9 38.5±16.5 48.3±20.2*
  Disease duration before HLH/months 22.7±66.9 21.4±43.0 11.3±26.9
Clinical and laboratory characteristics
  Fever (>38.5 ℃) 24/24 (100.0) 23/24 (95.8) 20/20 (100.0)
  Splenomegaly 18/24 (75.0) 13/24 (54.2) 15/20 (75.0)
  Hepatomegaly 1/24 (4.2) 4/24 (16.7) 5/20 (25.0)
  Lymphadenopathy 9/24 (37.5) 10/24 (41.7) 13/20 (65.0)
  Neurological involvement 4/24 (16.7) 3/24 (12.5) 7/20 (35.0)
  Disseminated intravascular coagulation 7/24 (29.2) 1/24 (4.2) 1/20 (5.0)
Cytopenia
  HB < 90 g/L 17/24 (70.8) 20/24 (83.3) 16/20 (80.0)
  PLT < 100×109/L 16/24 (66.7) 22/24 (91.7) 20/20 (100.0)*
  NE < 1×109/L 10/23 (43.5) 15/22 (68.2) 13/19 (68.4)
Hyperferritinemia (SF>500 μg/L) 24/24 (100.0) 23/24 (95.8) 18/19 (94.7)
Hypofibrinogenemia (FIBC < 1.5 g/L) 15/24 (62.5) 12/23 (52.2) 16/20 (80.0)
Hypertriglyceridemia (TG≥3 mmol/L) 14/24 (58.3) 13/23 (56.5) 10/10 (100.0)*#
LDH>250 U/L 23/24 (95.8) 24/24 (100.0) 18/20 (90.0)
Elevated aminotransferases
  ALT>40 U/L 23/24 (95.8) 15/23 (65.2)* 15/20 (75.0)
  AST>40 U/L 23/24 (95.8) 19/23 (82.6) 16/20 (80.0)
Hypoalbuminemia (ALB < 40 g/L) 23/24 (95.8) 24/24 (100.0) 19/20 (95.0)
Elevated ESR (>20 mm/h) 14/23 (60.7) 22/24 (91.7)* 19/20 (95.0)*
Elevated CRP(>8 mg/dL) 23/24 (95.8) 20/24 (83.3) 18/20 (90.0)
Hemophagocytosis in bone marrow 12/23 (52.2) 13/24 (54.2) 8/18 (44.4)
Low NK cell activity 8/21 (38.1) 9/17 (52.9) 6/10 (60.0)
Serum soluble CD25 receptor≥2 400 U/mL 16/17 (94.1) 14/17 (82.4) 9/10 (90.0)

图1

发生MAS时SLE及AOSD病程分布情况"

表2

不同疾病继发HLH患者的实验室指标的比较"

Items SLE (n=50) AOSD (n=50) SLE-MAS (n=24) AOSD-MAS (n=24) LYM-HLH (n=20)
WBC/(×109/L) 5.2
(1.0, 12.8)		 15.1
(4.9, 38.0)*#		 2.1
(0.2, 13.4)*		 3.8
(0.3, 27.0)		 1.7
(0.1, 6.4)
NE/(×109/L) 3.4
(0.7, 8.6)		 12.6
(3.3, 35.1)*#		 1.2
(0, 7.4)*		 2.6
(0, 24.2)		 1.1
(0, 5.5)
HB/(g/L) 107.8
(46.0, 180.0)		 107.3
(84.0, 129.0)#		 70.5
(40.0, 104.2)*#		 82.5
(49.0, 122.0)△		 70.4
(47.0, 136.0)
PLT/(×109/L) 155.8
(5.0, 381.0)		 305.0
(84.0, 576.0)*#		 42.8
(2.0, 134.0)*#△		 88.4
(7.0, 296.0)△		 23.6
(2.0, 90.0)
ESR/(mm/h) 31.8
(3.0, 92.0)		 72.3
(1.0, 133.0)*#		 66.6
(7.0, 120.0)*#		 32.0
(2.0, 78.0)		 44.6
(3.0, 129.0)
CRP/(mg/dL) 9.6
(0.3, 50.2)		 89.9
(4.0, 339.0)*		 60.4
(2.3, 364.0)*		 67.8
(7.5, 272.0)		 77.9
(3.0, 211.0)
ALT/(U/L) 33.0
(5.0, 215.0)		 19.8
(5.0, 73.0)*#		 109.4
(5.0, 619.0)*#		 715.8
(28.0, 3 550.0)△		 132.2
(11.0, 286.0)
AST/(U/L) 36.4
(9.0, 477.0)		 58.1
(11.0, 873.0)#		 308.5
(8.0, 1 424.0)*		 682.0
(14.0, 2 174.0)△		 203.5
(13.0, 665.0)
LDH/(U/L) 233.8
(120.0, 867.0)		 421.8
(140.0, 1 269.0)*#		 930.3
(360.0, 2 185.0)*#		 1 814.1
(244.0, 5 099.0)		 1 934.7
(170.0, 8 517.0)
TG/(mmol/L) 1.9
(0.4, 6.9)		 1.4
(0.7, 2.6)*#		 4.0
(1.4, 10.7)*		 3.2
(1.3, 5.8)△		 4.3
(1.0, 9.6)
ALB/(g/L) 34.9
(17.2, 46.8)		 33.1
(20.4, 41.0)*#		 24.6
(16.3, 34.2)*#		 29.3
(20.0, 40.0)△		 26.0
(19.0, 41.0)
FIBC/(mg/dL) 292.2
(123.0, 465.0)		 348.8
(178.0, 737.0)*#		 165.1
(26.0, 436.0)*		 139.0
(55.0, 307.0)		 129.6
(55.0, 349.0)
SF/(μg/L) 308.0
(11.0, 1 665.0)		 5 214.6
(522.0, 21 133.0)*#		 10 968.8
(455.0, 83 039.0)*#		 37 098.8
(2 000.0, 100 000.0)△		 18 364.7
(101.0, 63 917.0)

表3

对SLE-MAS诊断有提示意义的实验室指标及其截断值"

Items AUC Cutoff value Sensitivity Specificity
SF 0.983 ≥1 010 μg/L 0.95 0.96
LDH 0.973 ≥359 U/L 0.90 1.00
AST 0.898 ≥33.5 U/L 0.82 0.96
PLT 0.887 ≤93.5×109/L 0.86 0.92
WBC 0.869 ≤2.5×109/L 0.86 0.79
NE 0.864 ≤1.6×109/L 0.84 0.83
HB 0.859 ≤85 g/L 0.82 0.83
FIBC 0.857 ≤183.5 mg/dL 0.94 0.71
CRP 0.836 ≥23.5 mg/dL 0.90 0.63
ALB 0.830 ≤29.7 g/L 0.82 0.79
TG 0.823 ≥1.9 mmol/L 0.58 0.96
ALT 0.807 ≥30.5 U/L 0.72 0.83
ESR 0.804 ≥57.0 mm/h 0.86 0.63

表4

对AOSD-MAS诊断有提示意义的实验室指标及其截断值"

Items AUC Cutoff value Sensitivity Specificity
FIBC 0.988 ≤225.5 mg/dL 0.98 0.92
TG 0.953 ≥2.0 mmol/L 0.84 0.92
WBC 0.948 ≤6.3×109/L 0.96 0.92
NE 0.946 ≤4.3×109/L 0.98 0.92
AST 0.943 ≥110.0 U/L 0.97 0.96
PLT 0.941 ≤164.5×109/L 0.94 0.88
ALT 0.938 ≥74.5 U/L 0.86 0.92
LDH 0.915 ≥667.5 U/L 0.90 0.83
HB 0.900 ≤97.5 g/L 0.76 0.92
ESR 0.862 ≥59.5 mm/h 0.64 0.92
SF 0.833 ≥13 283.5 μg/L 0.88 0.63
ALB 0.758 ≤31.7 g/L 0.70 0.79
CRP 0.636 ≥54.9 mg/dL 0.72 0.58

表5

2016 sJIA-MAS分类标准在AOSD-MAS患者中的应用"

Items AOSD-MAS, n(%) AOSD, n(%) Sensitivity/% Specificity/% PPV/% NPV/%
Fulfilling criteria 24 (100.0) 19 (38.0) 100.0 62.0 56.0 100.0
SF>684 μg/L 24 (100.0) 46 (92.0) 100.0 8.0 34.0 100.0
PLT≤181×109/L 21 (87.5) 9 (18.0) 87.5 82.0 70.0 93.0
AST>48 U/L 23 (95.8) 15 (30.0) 95.8 70.0 61.0 97.0
TG>156 mg/dL 22 (91.7) 9 (18.0) 91.7 82.0 71.0 95.0
FIBC≤360 mg/dL 24 (100.0) 32 (64.0) 100.0 36.0 43.0 100.0

表6

改进2016 sJIA-MAS分类标准在AOSD-MAS患者中的应用"

Items AOSD-MAS, n(%) AOSD, n(%) Sensitivity/% Specificity/% PPV/% NPV/%
Fulfilling criteria 24 (100.0) 7 (14.0) 100.0 86.0 77.1 100.0
SF>2 000 μg/L 24 (100.0) 32 (64.0) 100.0 36.0 42.9 100.0
PLT≤181×109/L 21 (87.5) 9 (18.0) 87.5 82.0 70.0 93.0
AST>48 U/L 23 (95.8) 15 (30.0) 95.8 70.0 61.0 97.0
TG>156 mg/dL 22 (91.7) 9 (18.0) 91.7 82.0 71.0 95.0
FIBC≤225.5 mg/dL 23 (95.8) 1 (2.0) 95.8 98.0 95.8 98.0
1 Ravelli A , Minoia F , Davi S , et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative[J]. Ann Rheum Dis, 2016, 75 (3): 481- 489.
doi: 10.1136/annrheumdis-2015-208982
2 Henter JI , Horne A , Arico M , et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48 (2): 124- 131.
doi: 10.1002/pbc.21039
3 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40 (9): 1725.
4 Petri M , Orbai AM , Alarcon GS , et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64 (8): 2677- 2686.
doi: 10.1002/art.34473
5 Yamaguchi M , Ohta A , Tsunematsu T , et al. Preliminary criteria for classification of adult Still's disease[J]. J Rheumatol, 1992, 19 (3): 424- 430.
6 Vardiman JW , Harris NL , Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms[J]. Blood, 2002, 100 (7): 2292- 2302.
doi: 10.1182/blood-2002-04-1199
7 Swerdlow SH , Campo E , Pileri SA , et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127 (20): 2375- 2390.
doi: 10.1182/blood-2016-01-643569
8 Crayne CB , Albeituni S , Nichols KE , et al. The immunology of macrophage activation syndrome[J]. Front Immunol, 2019, 10, 119.
doi: 10.3389/fimmu.2019.00119
9 Lenert A , Oh G , Ombrello MJ , et al. Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database[J]. Rheumatology (Oxford), 2020, 59 (7): 1725- 1733.
doi: 10.1093/rheumatology/kez622
10 Ramos-Casals M , Brito-Zeron P , Lopez-Guillermo A , et al. Adult haemophagocytic syndrome[J]. Lancet, 2014, 383 (9927): 1503- 1516.
doi: 10.1016/S0140-6736(13)61048-X
11 姚海红, 王旖旎, 张霞, 等. 67例成人巨噬细胞活化综合征的临床特征及治疗转归[J]. 北京大学学报(医学版), 2019, 51 (6): 996- 1002.
doi: 10.19723/j.issn.1671-167X.2019.06.003
12 Liu AC , Yang Y , Li MT , et al. Macrophage activation syndrome in systemic lupus erythematosus: A multicenter, case-control study in China[J]. Clin Rheumatol, 2018, 37 (1): 93- 100.
doi: 10.1007/s10067-017-3625-6
13 Kumakura S , Murakawa Y . Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults[J]. Arthritis Rheumatol, 2014, 66 (8): 2297- 2307.
doi: 10.1002/art.38672
14 Sen ES , Clarke SL , Ramanan AV . Macrophage activation syndrome[J]. Indian J Pediatr, 2016, 83 (3): 248- 253.
doi: 10.1007/s12098-015-1877-1
15 Knovich MA , Storey JA , Coffman LG , et al. Ferritin for the clinician[J]. Blood Rev, 2009, 23 (3): 95- 104.
doi: 10.1016/j.blre.2008.08.001
16 Ravelli A , Minoia F , Davi S , et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis[J]. RMD Open, 2016, 2 (1): e000161.
doi: 10.1136/rmdopen-2015-000161
17 Gao Q , Yuan Y , Wang Y , et al. Clinical characteristics of macrophage activation syndrome in adult-onset Still's disease[J]. Clin Exp Rheumatol, 2021, 39 (5): 59- 66.
doi: 10.55563/clinexprheumatol/lp2u7g
18 Yang XP , Wang M , Li TF , et al. Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still's disease[J]. Clin Exp Rheumatol, 2019, 37 (6): 83- 88.
19 Wang R , Li T , Ye S , et al. Macrophage activation syndrome associated with adult-onset Still's disease: A multicenter retrospective analysis[J]. Clin Rheumatol, 2020, 39 (8): 2379- 2386.
doi: 10.1007/s10067-020-04949-0
20 Di Benedetto P , Cipriani P , Iacono D , et al. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort[J]. PLoS One, 2020, 15 (7): e0235326.
doi: 10.1371/journal.pone.0235326
21 Lehmberg K , McClain KL , Janka GE , et al. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2014, 61 (11): 2101- 2103.
doi: 10.1002/pbc.25058
22 Minoia F , Davi S , Horne A , et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients[J]. Arthritis Rheumatol, 2014, 66 (11): 3160- 3169.
doi: 10.1002/art.38802
23 Gauvin F , Toledano B , Champagne J , et al. Reactive hemophagocytic syndrome presenting as a component of multiple organ dysfunction syndrome[J]. Crit Care Med, 2000, 28 (9): 3341- 3345.
doi: 10.1097/00003246-200009000-00038
24 Wiwanitkit V . Bone marrow leishmaniasis: A review of situation in Thailand[J]. Asian Pac J Trop Med, 2011, 4 (10): 757- 759.
doi: 10.1016/S1995-7645(11)60188-0
25 刘燕鹰, 周姝含, 张莉, 等. 噬血细胞综合征77例临床分析[J]. 中华医学杂志, 2015, 95 (9): 681- 684.
doi: 10.3760/cma.j.issn.0376-2491.2015.09.011
26 Shimizu M , Mizuta M , Yasumi T , et al. Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2018, 70 (9): 1412- 1415.
doi: 10.1002/acr.23482
27 Tada Y , Inokuchi S , Maruyama A , et al. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?[J]. Rheumatol Int, 2019, 39 (1): 97- 104.
doi: 10.1007/s00296-018-4114-1
28 Bae CB , Jung JY , Kim HA , et al. Reactive hemophagocytic syndrome in adult-onset Still disease clinical features, predictive factors, and prognosis in 21 patients[J]. Medicine, 2015, 94 (4): e451.
doi: 10.1097/MD.0000000000000451
29 Hot A , Toh ML , Coppere B , et al. Reactive hemophagocytic syndrome in adult-onset Still disease clinical features and long-term outcome: A case-control study of 8 patients[J]. Medicine, 2010, 89 (1): 37- 46.
doi: 10.1097/MD.0b013e3181caf100
30 Lin SJ , Chao HC , Yan DC . Different articular outcomes of Still's disease in Chinese children and adults[J]. Clin Rheumatol, 2000, 19 (2): 127- 130.
doi: 10.1007/s100670050030
[1] 李正芳,罗采南,武丽君,吴雪,孟新艳,陈晓梅,石亚妹,钟岩. 抗氨基甲酰化蛋白抗体在诊断类风湿关节炎中的应用价值[J]. 北京大学学报（医学版）, 2024, 56(4): 729-734.
[2] 乔佳佳,田聪,黄晓波,刘军. 肾结石合并系统性红斑狼疮行经皮肾镜碎石取石术的安全性和有效性评估[J]. 北京大学学报（医学版）, 2024, 56(4): 745-749.
[3] 任立敏,赵楚楚,赵义,周惠琼,张莉芸,王友莲,沈凌汛,范文强,李洋,厉小梅,王吉波,程永静,彭嘉婧,赵晓珍,邵苗,李茹. 系统性红斑狼疮低疾病活动度及缓解状况的真实世界研究[J]. 北京大学学报（医学版）, 2024, 56(2): 273-278.
[4] 罗芷筠,吴佳佳,宋优,梅春丽,杜戎. 伴神经精神系统病变的系统性红斑狼疮相关巨噬细胞活化综合征2例[J]. 北京大学学报（医学版）, 2023, 55(6): 1111-1117.
[5] 赵祥格,刘佳庆,黄会娜,陆智敏,白自然,李霞,祁荆荆. 干扰素-α介导系统性红斑狼疮外周血CD56dimCD57+自然杀伤细胞功能的损伤[J]. 北京大学学报（医学版）, 2023, 55(6): 975-981.
[6] 熊焰,李鑫,梁丽,李东,鄢丽敏,李雪迎,邸吉廷,李挺. 甲状腺粗针穿刺活检病理诊断的准确性评估[J]. 北京大学学报（医学版）, 2023, 55(2): 234-242.
[7] 哈雪梅,姚永正,孙莉华,辛春杨,熊焰. 实性肺胎盘样变形1例及文献复习[J]. 北京大学学报（医学版）, 2023, 55(2): 357-361.
[8] 宁博涵,张青霞,杨慧,董颖. 伴间质细胞增生、玻璃样变性及索状结构的子宫内膜样腺癌1例[J]. 北京大学学报（医学版）, 2023, 55(2): 366-369.
[9] 陈适,刘田. 重视系统性血管炎的早期识别和个体化治疗[J]. 北京大学学报（医学版）, 2022, 54(6): 1065-1067.
[10] 张琳崎,赵静,王红彦,王宗沂,李英妮,汤稷旸,李思莹,曲进锋,赵明威. 抗ENO1抗体与狼疮性视网膜病变的相关性[J]. 北京大学学报（医学版）, 2022, 54(6): 1099-1105.
[11] 李敏,侯林卿,金月波,何菁. 系统性红斑狼疮合并视网膜病变的临床及免疫学特点[J]. 北京大学学报（医学版）, 2022, 54(6): 1106-1111.
[12] 邵苗,郭惠芳,雷玲彦,赵清,丁艳杰,林进,吴锐,于峰,李玉翠,苗华丽,张莉芸,杜燕,焦瑞英,庞丽霞,龙丽,栗占国,李茹. 短间期小剂量环磷酰胺治疗系统性红斑狼疮耐受性的多中心对照研究[J]. 北京大学学报（医学版）, 2022, 54(6): 1112-1116.
[13] 曹瑞洁,姚中强,焦朋清,崔立刚. 不同分类标准对中国大动脉炎的诊断效能比较[J]. 北京大学学报（医学版）, 2022, 54(6): 1128-1133.
[14] 邢晓燕,张筠肖,朱冯赟智,王一帆,周新尧,李玉慧. 皮肌炎合并巨噬细胞活化综合征5例[J]. 北京大学学报（医学版）, 2022, 54(6): 1214-1218.
[15] 徐朝焰,林长艺,叶达梅,吴培埕,宋明辉,刘有添,邓琼,黄雪艳,范忠晓,游雪兰. 感染性关节炎诊断分析[J]. 北京大学学报（医学版）, 2022, 54(6): 1234-1237.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 钟金晟, 欧阳翔英, 梅芳, 邓旭亮, 曹采方. 多孔β-磷酸三钙/胶原支架与犬牙周膜细胞三维复合体的构建[J]. 北京大学学报（医学版）, 2007, 39(5): 507 -510 .
[2] 张奇, 罗国安, 邓英杰. 均匀设计法制备5-氟尿嘧啶脂质体及其稳定性[J]. 北京大学学报（医学版）, 2002, 34(1): 64 -67 .
[3] 管宏, 赵慧云, 沈磊, 李五岭, 王建华, 王春荣, 徐福. 联合应用重组TPO和G-CSF对骨髓抑制性小鼠外周血小板及白细胞恢复的影响[J]. 北京大学学报（医学版）, 2001, 33(2): 181 -182 .
[4] 林涛, 李琳丽, 詹先成, 李开兰, 李志毅, 殷恭宽. 盐酸普鲁卡因注射液在光和热同时作用下的稳定性[J]. 北京大学学报（医学版）, 2001, 33(3): 247 -250 .
[5] 李云芳, 张幼怡, 侯嵘, 董尔丹, 韩启德. 质粒转染对HEK293和DDT1-MF2细胞天然β2-肾上腺素受体表达的影响[J]. 北京大学学报（医学版）, 2001, 33(5): 457 -461 .
[6] 柯杨. 乳头状瘤病毒与人类肿瘤[J]. 北京大学学报（医学版）, 2002, 34(5): 599 -603 .
[7] 赵建新, 周良, 万远廉. 经十二指肠逆行放置支架治疗恶性幽门梗阻2例[J]. 北京大学学报（医学版）, 2002, 34(6): 737 -738 .
[8] 洪涛, 霍勇. COURAGE试验后稳定型心绞痛的治疗策略思考[J]. 北京大学学报（医学版）, 2007, 39(6): 562 -564 .
[9] 牟向东, 王广发, 阙呈立, 李桂莲. H3N2型人流行性感冒合并金黄色葡萄球菌败血症及金黄色葡萄球菌肺炎1例[J]. 北京大学学报（医学版）, 2007, 39(6): 663 -665 .
[10] 李智岗, 黄景香, 李顺宗, 赵俊京, 时高峰, 梁国庆, 王红光, 韩捧银, 王琦, 谷铁树. 肝转移瘤的血供[J]. 北京大学学报（医学版）, 2008, 40(2): 146 -150 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部